Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA3 | P34903 | 7/20 | 0.63 |
| ▸ | GABRG2 | P18507 | 6/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 6/20 | 0.63 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.53 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.53 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.53 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7721717 | 0.89 | GABRG2 (0.64) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL29692345 | 0.89 | GABRA3 (0.76) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL13009537 | 0.89 | GABRA3 (0.76) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL13061672 | 0.88 | — | — | |
| SCHEMBL13061673 | 0.87 | GABRA3 (0.81) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL7724642 | 0.87 | GABRA3 (0.77) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL30056689 | 0.84 | GABRA5 (0.59) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL22717284 | 0.84 | GABRA5 (0.59) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL30056839 | 0.84 | GABRA5 (0.59) | GABRA3GABRG2GABRB3GABRA1GABRA5 | |
| SCHEMBL19922802 | 0.79 | GABRA3 (0.73) | GABRA3GABRG2GABRB3GABRA1GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4129297-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM Research Foundation, Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| US-20210309662-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2021-10-07 | — | — | US | disclosed |
| US-10906909-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists | UWM RESEARCH FOUNDATION, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200181146-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RESEARCH FOUNDATION, INC. | 2020-06-11 | — | — | US | disclosed |
| WO-2017161370-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | UWM RESEACH FOUNDATION, INC. (US) | 2017-09-21 | — | — | WO | disclosed |
| US-9597342-B2 | GABAergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. | 2015-09-17 | — | — | US | disclosed |
| US-9006233-B2 | Gabaergic receptor subtype selective ligands and their uses | UWM RESEARCH FOUNDATION, INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-8835424-B2 | Selective agents for pain suppression | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120295892-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | UWM RESEARCH FOUNDATION, INC. (US) | 2012-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11753412-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with Alpha5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | GABRA3 5/4885GABRG2 25/4885GABRB3 10/4885 |
| US-20200181146-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | GABRA5, CHRNA5, GABRA1 | GABRA3 5/4885GABRG2 25/4885GABRB3 10/4885 |
| US-20150258128-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | GABRA3, GABRA2, GABRB3 | GABRA3 1/4885GABRG2 10/4885GABRB3 3/4885 |
| US-20210309662-A1 | TREATMENT OF COGNITIVE AND MOOD SYMPTOMS IN NEURODEGENERATIVE AND NEUROPSYCHIATRIC DISORDERS WITH ALPHA5-CONTAINING GABAA RECEPTOR AGONISTS | GABRA5, CHRNA5, GABRA1 | GABRA3 5/4885GABRG2 25/4885GABRB3 10/4885 |
| US-20120295892-A1 | GABAERGIC RECEPTOR SUBTYPE SELECTIVE LIGANDS AND THEIR USES | GABRA3, GABRA2, GABRB3 | GABRA3 1/4885GABRG2 10/4885GABRB3 3/4885 |
| US-10906909-B2 | Treatment of cognitive and mood symptoms in neurodegenerative and neuropsychiatric disorders with ALPHA5-containing GABAA receptor agonists | GABRA5, CHRNA5, GABRA1 | GABRA3 5/4885GABRG2 25/4885GABRB3 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.